|
|
 Previous Article | Table of Contents | Next Article 
Prognostic implications of tumor cell DNA and RNA content in multiple
myeloma
B Barlogie, R Alexanian, D Dixon, L Smith, L Smallwood and K Delasalle
Flow cytometric studies of bone marrow DNA and RNA content were conducted
in 71 previously untreated patients with multiple myeloma. There was a
progressive increase in response rate with rising plasma cell RNA content.
The DNA-derived ploidy level also affected chemotherapy sensitivity: only
one of 11 patients with either hypodiploidy or biclonal DNA stemlines
responded. DNA-RNA-defined marrow plasmacytosis was the only tumor
mass-related variable adversely affecting remission induction. Survival was
longer in patients with low tumor burden and favorable DNA features. The
availability of objective and quantitative pretreatment variables
associated with both initial response and survival should permit a
risk-based selection of patients for novel treatment approaches.
Volume 66,
Issue 2,
pp. 338-341,
08/01/1985
Copyright © 1985 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al.
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Blood,
April 15, 2007;
109(8):
3489 - 3495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc.,
March 1, 2007;
82(3):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, C. S. Debes-Marun, E. B. Picken, G. W. Dewald, S. C. Bryant, J. M. Winkler, E. Blood, M. M. Oken, R. Santana-Davila, N. Gonzalez-Paz, et al.
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
Blood,
October 1, 2003;
102(7):
2562 - 2567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moreau, T. Facon, X. Leleu, N. Morineau, P. Huyghe, J.-L. Harousseau, R. Bataille, and H. Avet-Loiseau
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
Blood,
August 13, 2002;
100(5):
1579 - 1583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. V. Smadja, C. Bastard, C. Brigaudeau, D. Leroux, and C. Fruchart
Hypodiploidy is a major prognostic factor in multiple myeloma
Blood,
October 1, 2001;
98(7):
2229 - 2238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, T. Facon, A. Daviet, C. Godon, M.-J. Rapp, J.-L. Harousseau, B. Grosbois, and R. Bataille
14q32 Translocations and Monosomy 13 Observed in Monoclonal Gammopathy of Undetermined Significance Delineate a Multistep Process for the Oncogenesis of Multiple Myeloma
Cancer Res.,
September 1, 1999;
59(18):
4546 - 4550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Garcia-Sanz, A. Orfao, M. Gonzalez, M.D. Tabernero, J. Blade, M.J. Moro, J. Fernandez-Calvo, M.A. Sanz, J.A. Perez-Simon, A. Rasillo, et al.
Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics
Blood,
February 1, 1999;
93(3):
1032 - 1037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Dimopoulos, B. Barlogie, T. L. Smith, and R. Alexanian
High Serum Lactate Dehydrogenase Level as a Marker for Drug Resistance and Short Survival in Multiple Myeloma
Ann Intern Med,
December 15, 1991;
115(12):
931 - 935.
[Abstract]
[PDF]
|
|
|
|
|
